Boston, Massachusetts – September 10, 2026
Researchers at the MIT Media Lab have developed HITMAN, a wireless bioelectric therapy that selectively eradicates drug-resistant glioblastoma cells through magnetically activated nanoantennas. The technology demonstrated 52% cell elimination in laboratory studies and extended median survival by more than 50% in animal models without detectable toxicity to healthy tissue.
Glioblastoma remains one of the most aggressive and lethal primary brain tumors, with a median survival of just 12-15 months even with standard care. Surgical resection is limited by the tumor's infiltrative nature, and conventional chemotherapy and radiotherapy often fail due to intrinsic resistance mechanisms.
Study Scale and Design
The research team worked with tumor tissue obtained from patients diagnosed with aggressive, chemotherapy-resistant glioblastoma at Mayo Clinic. In vitro experiments compared HITMAN against temozolomide (TMZ) using patient-derived xenograft (PDX) line-315 cells, which have confirmed MGMT unmethylated status—a well-documented mechanism of intrinsic chemotherapy resistance.
For in vivo testing, the researchers implanted patient-derived tumor cells into the brains of mice, creating orthotopic models widely regarded as the gold standard for preclinical brain tumor research. HITMAN nanoantennas were activated wirelessly using low-frequency magnetic fields (≤200 kHz) that penetrate the intact skull and brain tissue.
"HITMAN offers a minimally invasive, spatially precise, and clinically translatable therapy for glioblastoma," the researchers write in their paper.
Key Findings
Selective Cell Death
HITMAN targets cancer cells while sparing healthy neurons and brain-supporting astrocytes. The therapy works through magnetoelectric transduction—magnetically actuated nanoantennas (MANs) convert external magnetic fields into localized electric fields at the cellular level, reaching magnitudes exceeding 2 kV/m. These nanoscale electric fields trigger protein unfolding, membrane damage, and endoplasmic reticulum stress.
The selective targeting occurs due to cancer cells' high proliferative rate, which elevates protein-folding demand, as well as their characteristic abnormalities in membrane composition and intracellular organelles.
Tumor Growth Inhibition
In orthotopic mouse models, HITMAN substantially inhibited tumor growth. The therapy reduced the number of cancer cell colonies from 112-150 in control groups to just 26 in the experimental group, suggesting significant potential to reduce tumor recurrence and metastasis.
Mechanistic Insights
Comprehensive transcriptomic and proteomic analyses revealed that HITMAN disrupts cellular integrity through multiple pathways. The therapy activates the unfolded protein response and autophagy pathways, suppresses cell cycle and adhesion genes, reduces Ki-67 expression, disrupts cytoskeletal architecture, and elevates p53 levels.
Control experiments confirmed the therapeutic effects are specifically due to the magnetoelectric interaction. Glioblastoma cells exposed to nanoantennas without magnetic fields, to magnetic fields alone, or to magnetostrictive devices without piezoelectric shells showed no significant cytotoxicity.
Clinical Translation Path
The HITMAN nanoantennas measure approximately 150 nanometers and could be injected through the skull if translated to clinical use. Researchers have developed a complementary technology called "circulatronics" that could simplify deployment further—allowing devices to be administered through an injection in a patient's arm and travel to target brain regions via the bloodstream.
The circulatronics approach integrates electronic devices with living cells to evade the immune system and cross the blood-brain barrier, as demonstrated in pre-clinical studies.
"The persistent failure of these therapies underscores the urgent need for novel approaches to target treatment-resistant glioblastoma cells," the researchers write.
Research Collaboration
The open-access paper appears in Science Advances on September 9, 2026. Sarkar is joined on the paper by members of her lab, including Monochura Saha, Ishaq Khan, Baju Joy, Shun Ying Chen, Hao-Tung Yang, Preet Patel, and Pengrui Zhang, all MIT graduate students, and Faheem Azeemi, an MIT undergraduate student.
The work addresses a critical unmet clinical need. Despite decades of research, glioblastoma treatment has seen minimal improvement in overall survival. Surgical resection is constrained by infiltrative tumor growth, radiotherapy and chemotherapy are hindered by resistance mechanisms, and immunotherapy faces an immunosuppressive tumor microenvironment.
Source: Science Advances, September 9, 2026. MIT News, September 9, 2026.
FIRAT Editorial Board
Institutional Research Desk · Foresight Institute of Research and Translation
The collective editorial and research translation board of FIRAT, synthesising peer-reviewed evidence, policy briefs, and division milestones across our seven foundational research pillars.
